Scilex appoints Annu Navani, M.D. as Class II director and committee member

Scilex Holding Co

Appointed Annu Navani, M.D. as Class II director effective July 21, 2024; she will serve on the Commercialization and Transaction Committee.
Dr. Navani is CEO of Comprehensive Spine and Sports Center and CMO of Boomerang Healthcare; Clinical Professor at Stanford.
Granted initial stock option for 250,000 shares vesting monthly over 48 months under Non-Employee Director Compensation Policy.
No family relationships or related-party transactions; standard indemnification agreement entered.
Press release issued July 23, 2024 announcing the appointment.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Annu Navani, M.D.

Class II director

SCLX · Scilex Holding Co

Effective: 2024-07-21
Filed: July 25, 2024, 7:59 PM ET

On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Annu Navani, M.D. was appointed as Class II director at Scilex Holding Co.

Action: appointed
Role: Class II director

Exact text from the filing

On July 21, 2024, Scilex Holding Company (the “ Company ”) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the “ Board ”).

View on SEC.gov

Scilex Holding Co filing history →

Source: SEC EDGAR

accession 0000950170-24-086629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.